Wat is de prijs voor Aerpio Pharmaceuticals, Inc. (ARPO)

Het prijs van Aerpio Pharmaceuticals, Inc. (ARPO) is $2.20

Wat is de marktkapitalisatie voor Aerpio Pharmaceuticals, Inc. (ARPO)

Marktkapitalisatie voorAerpio Pharmaceuticals, Inc. (ARPO) is $40.53M

Aerpio Pharmaceuticals, Inc. (ARPO) Uitstaande Aandelen

Aerpio Pharmaceuticals Inc., a biopharmaceutical enterprise headquartered in Blue Ash, Ohio, currently employs 27 full-time staff. The company's core mission revolves around the research and development of therapeutic solutions for ocular diseases. Its product pipeline is spearheaded by AKB-9778, with two additional programs, AKB-4924 and ARP-1536, also under development. AKB-9778 is a small molecule designed to activate the Tie-2 pathway, intended for the treatment of diabetic retinopathy (DR). AKB-4924, another candidate, functions as a selective stabilizer of hypoxia-inducible factor-1 alpha (HIF-1alpha) and is being investigated for its potential in treating inflammatory bowel disease (IBD). ARP-1536 is a humanized monoclonal antibody that targets the same pathway as AKB-9778. It operates by attaching to the extracellular domain of vascular endothelial protein tyrosine phosphatase (VE-PTP), thereby inhibiting its interaction with Tie-2. As of April 14, 2017, Aerpio had successfully concluded a Phase II clinical trial for AKB-9778, which involved 144 patients with diabetic macular edema. By the same date, a Phase Ia clinical trial for AKB-4924 in healthy volunteers had also been completed.

Jaar	Uitstaande aandelen	Wijzigen
Niet genoeg gegevens voor de verstrekte datums.

Jaar

Uitstaande aandelen

Wijzigen

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	Uitstaande aandelen	Verschil	Land
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	-	US
Argenx SE ARGX.US	62.19M	-	NL
CSL Limited CSL.AX	483.58M	-	AU
Lonza Group AG LONN.SW	-	-	CH
Moderna, Inc. MRNA.US	396.00M	-	US

Bedrijf

Uitstaande aandelen

Verschil

Land